The first microalgae platform for the production of anticancer biopharmaceutical...
The first microalgae platform for the production of anticancer biopharmaceuticals
Manufacturing costs remain one of the major obstacles to providing effective treatment of cancer patients. Anticancer agents are often complex biopharmaceuticals that are expensive to manufacture, requiring use of living cell line...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
FCDE10-1E-221
Biorreactores de Escala Media para la Obtención de Moléculas...
103K€
Cerrado
IPT-2011-1531-010000
PRODUCCIÓN DE UNA PROTEÍNA HUMANA DE USO TERAPÉUTICO EN BIOF...
549K€
Cerrado
AlgaeNet4AV
Training network for exploring microalgae diversity for the...
Cerrado
SAF2011-28883-C03-02
BIOTECNOLOGIA INDUSTRIAL DE MICROALGAS MARINAS DINOFLAGELADA...
133K€
Cerrado
BIO2015-64161-R
APLICACION DE ESTRATEGIAS BASADAS EN SECUENCIACION DE GENOMA...
321K€
Cerrado
Información proyecto MABIOS
Duración del proyecto: 6 meses
Fecha Inicio: 2019-07-05
Fecha Fin: 2020-01-31
Líder del proyecto
MICROALGAE WORKS BV
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Manufacturing costs remain one of the major obstacles to providing effective treatment of cancer patients. Anticancer agents are often complex biopharmaceuticals that are expensive to manufacture, requiring use of living cell lines with difficult-to-control production processes, limited yields and time-consuming purification steps. There is an urgent unmet need for an improved manufacturing process of biopharmaceuticals, to meet the high demand and lower the price of oncologic treatments. We will revolutionize the way biopharmaceuticals are produced by developing a microalgae based biorefinery platform. These biorefineries will utilize genetically engineered microalgae to efficiently produce pharmaceutical agents. Microalgae are photosynthetic micro-organisms that have unique advantages as biopharmaceutical production systems, including high growth rate, ease of cultivation and low growth costs, enabling cost effective and scalable yield of active ingredients. These will be recombinant proteins, small molecules or therapeutic peptides, starting with Paclitaxel as showcase, one of the world’s best sold anticancer drugs used as the first line treatment of a several solid tumours. Our platform has the potential to become the new manufacturing method of choice for production of highly needed biopharmaceuticals. Microalgae Works is an ambitious Dutch start-up with the mission to make anticancer treatment affordable for every patient through a drastic reduction of manufacturing costs. We are supported by leading companies in the field of biomanufacturing. The MABIOS project will (1) create a clear overview of the market opportunity for micro-algae based production of paclitaxel, (2) develop a de-risked plan for the technical development of our platform, (3) evaluate the necessary regulatory roadmap to enter the market, and (4) formulate an investor-proof business plan. We aim to become the frontrunner in biopharmaceutical production utilizing microalgae.